Blood Pressure, Endothelial Dysfunction
Conditions
Keywords
Endothelium
Brief summary
The primary purpose of this project is to assess the efficacy (effectiveness) of plant-based nitrate tablets to elevate nitric oxide in your system as measured by saliva and effect on lowering blood pressure (BP), supporting blood vessel function in men and women with hypertension.
Detailed description
This clinical trial is to assess the efficacy of plant-based bioequivalent Nitric Oxide supplement for improving blood pressure and endothelial reactivity over a 12 weeks intervention period in individuals with metabolic syndrome. The study also examines the effect of plant-based bioequivalent Nitric Oxide supplement on other markers of cardiovascular function and cardiovascular disease risk including Total, LDL and HDL-Cholesterol, Triglycerides, and a multitude of inflammatory markers.
Interventions
DIETARY_SUPPLEMENTPlant based bioequivalent Nitrate supplementation
The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
DIETARY_SUPPLEMENTPlacebo
Placebo
Sponsors
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Double Blind Placebo Controlled
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* age 40-75 years * Hypertension \>130/85 mmHg; men and women, 1:1 and stable medicated hypertensives * Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them
Exclusion criteria
* Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study * Weight in excess of 250 pounds * Bleeding disorder * History of known coronary artery disease, myocardial infarction, stroke or life-threatening arrhythmia within the prior six months * NYHA Class II- IV heart failure * History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy * Serum creatinine \> 1.4 mg/dl * Triglycerides \> 400 at visit 1 * Drug or alcohol abuse, or current intake of more than 14 standard drinks per week * Concurrent enrollment in another placebo-controlled trial * Partial ileal bypass or known gastrointestinal disease limiting drug absorption * Current tobacco use * Current use of anticoagulants (except for anti-platelet agents) * Renal failure * History of hypertensive encephalopathy or cerebrovascular accident * Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of change in blood pressure | 12 weeks | change in blood pressure (in millimeters of mercury) over twelve weeks under effect of active treatment and placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in serum, plasma and salivary Nitrite and Nitrate | 12 weeks | change in serum nitrate and nitrate levels (in mcg) over 12 weeks comparing active treatment to placebo |
| cardiometabolic relevant biomarkers (as compared to placebo) | 12 weeks | measures of serum markers of inflammation (Crp) and glucose over 12 weeks in active vs placebo arms |
Countries
United States
Outcome results
None listed